Physician Guide
Non-Opioid Intrathecal Therapy Pain Medication
IMPORTANT SAFETY INFORMATION
WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS
PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.

Patient Journey and Role of PRIALT in Managing Severe Chronic Pain

Page 1 of 2

In this video presentation, Dr. Peter S. Staats* discusses the role of PRIALT in managing severe chronic pain. Dr. Staats is immediate Past President for the American Society of Interventional Pain Physicians and a Partner at Premier Pain Centers, a pain management practice with seven locations throughout New Jersey.
 

 

Key Takeaway Points

Patients with severe chronic pain frequently experience multiple trials with various analgesics, including different opioids, different formulations, and routes of administration. In patients who are refractory to or intolerant of systemic analgesics, targeted drug delivery using an IT pump is one option that may break the cycle of inadequate pain relief and PRIALT may be an appropriate first-line IT option for these patients.

*Peter S. Staats, MD is a paid consultant for Jazz Pharmaceuticals.

INDICATION
PRIALT® (ziconotide) intrathecal infusion (25mcg/mL, 100mcg/mL) is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.

©2016 Jazz Pharmaceuticals plc or its subsidiaries.
US-PRI-0186 REV 0916
Last updated on: June 20, 2017
SHOW MAIN MENU
SHOW SUB MENU